Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: A prospective, multicenter, longitudinal study
暂无分享,去创建一个
Bing Ma | Qiong-rui Zhao | Youhua Yuan | Jiangfeng Zhang | W. Yan | Baoya Wang | Nan Jing | Qi Zhang | Zhibin Wang | Yi Li | Shan-mei Wang | Junhong Xu | Guo-Ning Chen
[1] D. Parums. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir , 2022, Medical science monitor : international medical journal of experimental and clinical research.
[2] J. Domingo. An updated review of the scientific literature on the origin of SARS-CoV-2 , 2022, Environmental Research.
[3] J. Domingo. What we know and what we need to know about the origin of SARS-CoV-2 , 2022, Environmental Research.
[4] A. Pollard,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial , 2022, The Lancet.
[5] Y. Siaw,et al. Intention to receive a COVID-19 vaccine booster dose and associated factors in Malaysia , 2022, Human vaccines & immunotherapeutics.
[6] Wei Chen,et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial , 2022, The Lancet Respiratory Medicine.
[7] Caijun Sun,et al. Acceptance of COVID‐19 booster vaccination based on the protection motivation theory: A cross‐sectional study in China , 2022, Journal of medical virology.
[8] Y. Lau,et al. Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study. , 2022, Vaccine.
[9] M. Mni,et al. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections , 2022, Frontiers in Immunology.
[10] H. Naruse,et al. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2 , 2022, Microbiology spectrum.
[11] G. Screaton,et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.
[12] U. V. Ukah,et al. COVID-19 vaccine hesitancy in Africa: a scoping review , 2021, Global Health Research and Policy.
[13] Yaolong Chen,et al. COVID-19 vaccine guidelines was numerous in quantity but many lack transparent reporting of methodological practices , 2021, Journal of Clinical Epidemiology.
[14] Wenhong Zhang,et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern , 2021, Cell research.
[15] M. Exline,et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. , 2021, JAMA.
[16] N. Gupta,et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses , 2021, The Lancet Infectious Diseases.
[17] G. Gao. Science-based COVID-19 vaccine development , 2021, National science review.
[18] Denis Sauré,et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study , 2021, The Lancet Infectious Diseases.
[19] Yihan Lu,et al. COVID-19 vaccine coverage, concerns, and preferences among Chinese ICU clinicians: a nationwide online survey , 2021, Expert review of vaccines.
[20] A. Huppert,et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers , 2021, The Lancet Respiratory Medicine.
[21] A. Borobia,et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.
[22] A. Saven,et al. ABO phenotype and clinical correlates of COVID-19 severity in hospitalized patients , 2021, Future science OA.
[23] M. Davenport,et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 , 2021, Nature communications.
[24] D. Engeler,et al. Prostatic Artery Embolisation Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: 2-yr Outcomes of a Randomised, Open-label, Single-centre Trial. , 2021, European urology.
[25] Zigui Chen,et al. Acceptance of the COVID-19 vaccine based on the health belief model: A population-based survey in Hong Kong , 2021, Vaccine.
[26] Fulian Yin,et al. Unfolding determinants of COVID-19 vaccine acceptance in China. , 2020, Journal of medical Internet research.
[27] A. Shaw,et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.
[28] N. Tatonetti,et al. Associations between blood type and COVID-19 infection, intubation, and death , 2020, Nature Communications.
[29] T. Lam,et al. Exposure to health misinformation about COVID-19 and increased tobacco and alcohol use: a population-based survey in Hong Kong , 2020, Tobacco Control.
[30] Stephen H. Bell,et al. A ?scoping review. , 2018, Sexual health.